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ABSTRACT
Objectives: Tumor endothelial marker 7 (TEM7) and nestin have been proposed to be new candidates for neoangiogenesis 
assessment. Nestin is also cancer stem cells marker in various malignant tumors. AIMS. To investigate the expression of 
TEM7, nestin and nestin-related microvessel density (MVD) in high-grade serous ovarian cancer samples and to study their 
correlation with overall survival (OS) and disease-free survival (DFS) times. 
Material and methods: Tumor samples obtained from 70 women with FIGO IIIc/IV ovarian serous cancer were studied 
with immunohistochemistry. 
Results: Patients median age was 54 yrs (range: 29–72 years), 86% died of the disease with median OS = 28.5 months and 
median DFS = 10 months (3 years DFS = 19%; 5 years. DFS = 13.8%). High nestin expression was found in 16 (23%) patients 
with 3 years and 5 years OS of 14% and 0%. In low-nestin expression group OS and DFS were 42% and 25%, respectively. 
Median nestin-MVD (16, range:12–23) was not correlated with cancer cells nestin expression and with both DFS and OS. 
High TEM7 expression was found in 29 women (41%) of whom 21 (72%) died of the disease. A 5-year OS in these women 
was 27% as compared to 8% in low TEM7 expression group, but TEM7 presence had no association with nestin, nestin-MVD 
and both OS and DFS. 
Conclusions: Nestin as a marker of cancer stem cells may assist in the prediction of OS and DFS in women with high grade 
serous ovarian cancer. Nestin may also be considered a novel therapeutic target for antiangiogenic agents.
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INTRODUCTION
Ovarian epithelial cancer has the highest mortality rate 
of all gynecological malignancies and the vast majority of 
the ovarian cancer deaths is related to advanced clinical 
stages of high-grade serous ovarian carcinoma (HGSOC) [1]. 
Most cases of HGSOC possess a relatively simple muta-
tional profile with TP53 nearly always mutated and with 
other genes mutated at low frequency [2]. During last two 
decades only a small improvement in overall survival has 
been achieved. Since HGSOC is a molecularly and clinically 
heterogeneous disease, this perspective may not be valid 
any more in the era of personalized therapy, and given that 
high-grade serous cancer is extremely sensitive and other 
subtypes are relatively resistant to chemotherapy [3–5]. 
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Targeting tumor angiogenesis has been validated as a the-
rapeutic strategy in the treatment of different malignancies, 
including high grade and recurrent ovarian cancer [6, 7]. An 
expanded research dedicated to discover new agents capa-
ble of targeting the endothelial layer of malignant tumors 
microvessels has resulted in discovery of the TEM proteins 
family and nestin [8, 9]
Nestin belongs to intermediate filament proteins group 
and since its discovery was believed to be associated solely 
with neural progenitor cells. Studies performed later reve-
aled that this protein may also be involved in malignant 
tumors neoangiogenesis and more recently nestin has been 
also documented to be one of cancer stem cells markers [10]. 
Although nestin is expressed at the early stages of normal 
human development it was also found in several physiolo-
gical conditions like e.g. in tissue repair processes through 
proliferating vascular endothelial cells or in various mali-
gnant tumors. Previous studies showed that nestin could 
be another specific indicator of ovarian cancer aggressive 
and clinically advanced forms [11, 12]. Correlation between 
nestin expression in tumor tissue and the clinical course of 
the disease was reported for breast and ovarian cancers, 
as well as for gastrointestinal tumors, germ cell tumors, 
osteosarcomas and melanomas [10]. In some tumor types, 
increased nestin expression correlates with the tumor gra-
de and indicates an immature and invasive phenotype of 
transformed cells [11, 12]. Interestingly, the use of nestin 
as a predictive marker of a poor response to conventional 
therapy and to novel therapeutic agents was reported for 
multiple myeloma [13]. 
A novel group of Tumor Endothelial Markers (TEMs) 
could be potentially used as new markers for immunohi-
stochemical assessment of microvessel network formation 
in various cancers [8, 14]. TEMs are proteins found in vario-
us malignant tumors tissue with much higher expression 
when compared to endothelial cells of microvessels fo-
und in healthy tissues. Important members of TEM family, 
and also the most promising candidates indicating can-
cer neoangiogenesis markers are: TEM1, TEM5, TEM7, and 
TEM8 [14, 15]. Special attention has been given to TEM7, 
a transmembrane protein that can also be found as a bound 
form, as well as soluble and secreted forms [14, 16]. Tumor 
endothelial marker 7 (TEM7) was initially identified as the 
most abundantly expressed gene in a group of cell surface 
proteins in the vascular endothelium of human tumors 
[8, 17, 18]. Overexpression of TEMs, and in particular TEM7 in 
ovarian cancer compared to benign masses and normal 
ovarian tissue suggests its possible role in tumor microvessel 
formation [14]. Because of these properties, TEMs appear to 
be perspective candidates for early detection, monitoring, 
and treatment of aggressive forms of EOC. 
The aims of this study were to investigate the expression 
of TEM-7, nestin and nestin-related microvessel density 
(MVD) in high-grade serous ovarian cancer samples and 
to examine their correlation with overall survival (OS) and 
disease-free survival (DFS) times of affected women.
MATERIAL AND METHODS
Patients and tumor samples
Clinical and demographical data were collected from 
a group of 70 patients with FIGO stage IIIc/IV of high grade 
ovarian serous cancer. Samples of cancer tissues were 
acquired following surgery and prior to chemotherapy 
from the Department of Molecular Pathology of the Maria 
Sklodowska-Curie Memorial Cancer Center and Institute of 
Oncology, Warsaw, Poland. The material was selected out of 
199 women with serous ovarian cancer who were treated in 
this hospital between 2000–2005. The clinical characteristics 
of these patients with p53 mutational status and outcome 
data following standardized chemotherapy regimens have 
been previously described [19]. All women in the present 
study met several inclusion criteria, among them an ad-
equate staging procedure that included total hysterectomy 
with bilateral salpingo-oophorectomy and omentectomy, 
aspiration of ascites or multiple cytologic washings, and 
multiple peritoneal biopsies including the diaphragm. In all 
cases complete abdominal exploration followed by pelvic 
and paraaortic lymph node sampling or complete paraaortic 
lymphadenectomy was performed. In all women 3-years and 
5 years OS and DSF rates were calculated and compared to 
their menopausal status, residual tumor size, chemotherapy 
sensitivity, the p53 protein mutational status and next with 
TEM7 and nestin expression as well as nestin microvascular 
density (MVD).
Imunohistochemical staining procedure was performed 
on paraffin-embedded tissues probe cut in 5 μm-thick sec-
tions and placed on silanized slides according to method 
described previously [12]. Tumor tissue slides were incu-
bated with the primary anti-nestin antibody (Sigma-Aldrich) 
(1:150) or anti-TEM7 antibody (Sigma-Aldrich) (1:200) for 
60 min at room temperature. The DAKO rabbit/mouse EnVi-
sion©+ HRP System were used for detection. Sections were 
counterstained with hematoxylin. To ensure tissue quality 
basic routine H+E staining was performed for all specimens.
The average number of nestin+ microvessels within 
selected tumor areas was measured according to standard 
Weidner’s MVD scoring method as previously described 
[12]. To identify the most vascularized areas of the tumors 
with the highest density of nestin+ microvessels sections 
were examined at low magnifications (×40 and ×100). Then, 
as a rule, 10 fields were examined, except in a few cases 
where less tumor tissue was available. The mean numbers 
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of vessels were expressed as the average of all fields ex-
amined at high magnification (×200); per high power field 
(nestin-MVD/HPF). Nestin and TEM7 expression in tumor 
cells was evaluated semi-quantitatively. Intensity of staining 
reaction and percentage of stain-positive cells were mea-
sured under ×200 magnification. The intensity of staining 
was classified “0” for absent staining, “1” for weak, “2” for 
moderate, and “3” for intense reaction. The proportion of 
stain-positive cells was visually calculated and cell expres-
sion was stratified as follows: low; for < 20% positive cells 
(weak or absent staining reaction), medium 21–50% positive 
cells (weak or moderate staining reaction) and high > 51% 
of positive cells (moderate or strong staining reaction).
Statistical analysis
Statistical analysis was performed with the use of Statis-
tica v.10.0 software (Statsoft, Poland). Association between 
categorical variables was examined by Pearson’s χ2 test 
or Fisher’s exact tests, where appropriate. Mann-Whitney 
nonparametric test was used to compare categorical with 
continuous tumor variables when there were two catego-
ries, whereas Kruskal-Wallis nonparametric test was used 
instead, when there were more than two categories. Overall 
survival (OS) and disease-free survival (DFS) was estimated 
using the Kaplan–Meier method. We analyzed the 3-year 
and 5-year survival rates of patient groups with different 
TEM7 and nestin-related parameters. OS and DFS were cal-
culated with the multivariate Cox’ proportional hazards 
model. The criterion of statistical significance applied in all 
calculations was p < 0.05. The study was approved by the 
Medical University of Lublin Bioethical Committee. 
RESULTS
Selected characteristics of the studied ovarian cancer 
patient cohort are presented in Table 1. Patients median age 
was 54 years. (range: 29–72 years), 86% died of the disease 
and with median overall survival time was 28.5 months 
and median DFS time was 10 months. As expected, the 
probability of survival was higher if the residual tumor 
size was smaller or complete cytoreduction was achie-
ved. Chemotherapy sensitivity was another statistically 
significant and important predictive factor for OS and DSF. 
The results of survival analysis according to clinical futures 
are shown in Table 1. Figures 1 and 2 present the typical 
nestin staining pattern in ovarian cancer tissues. Nestin 
protein was predominantly localized in the cytoplasm of 
cancer cells and also in endothelial cells around small ca-
pillaries. Figures 3 and 4 show typical expression pattern 
of TEM7 in tumor cells. Table 2 presents OS and DSF rates 
compared to TEM/nestin expression and according to ne-
stin microvessel density. There were statistically significant 
differences in OS and DSF rates between groups with low 
and high nestin expression in tumor cells (p = 0.02 and 
p = 0.01, respectively). High nestin expression was found 
in 14 patients. In this group OS was 14% after 3 years 
and 0% after 5 years. Corresponding DSF rates in these 
Table 1. Selected clinical features overall survival (OS) rates and disease free survival (DSF) in the studied group of women with HGSOC
N (no. of 
patients)
OS
3-year
OS
5-year p
DSF
3-year
DSF
5-year P
All group 70 37% 22% 18% 15%  
Residual tumor size
0 11 54% 27%
p = 0.03
46% 35%
p = 0.009
< 0.5 cm 5 46% 22% 16% 16%
0.5–2 cm 16 31% 15% 14% 14%
2–5 cm 4 50% 25% 25% 25%
5 cm 24 25% 13% 6% 6%
P53 mutation
No 27 16% 16%
p = 0.12
14% 14%
p = 0.51
Yes 43 49% 26% 19% 16%
Menopausal status
Before MNP 27 50% 25%
p = 0.13
27% 22%
p = 0.21
After MNP 43 29% 20% 11% 11%
Chemotherapy treatment sensitivity
Resistant 34 21% 8%
p = 0.00001
0% 0%
p < 0.0005Moderatly sensitive 24 27% 0% 5% 5%
Highly sensitive 12 91% 83% 75% 65%
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Figure 1. Nestin staining in ovarian cancer tissues. Nestin protein 
is predominantly localized in cytoplasm of endothelial cells around 
small capillaries (open arrows) and in tumor cells (full arrows). 
Magnification: x100
Figure 2. Selected area of nestin staining of ovarian cancer cells (full 
arrow) and microcapillaries (open arrow). Magnification: x400
Figure 3. Expression of TEM-7 in tumor cells of High Grade Serous 
Ovarian Cancer. Magnification: x100
Figure 4. Selected area of Fig. 3 with TEM-7 expression in cancer cells 
of High Grade Serous Ovarian Cancer. Magnification: x200
women were 9% and 0% after 3 and 5 years, respectively. In 
the group with low or medium nestin expression OS rates 
were more than 40% after 3 years and more than 20% after 
5years (Tab. 2). Nestin-MVD (median 16, range: 12–23) did 
not correlate with nestin expression in cancer cells. OS and 
DSF rates were not significantly different when high and 
low nestin density in tumor microvessels was considered 
(Tab. 2). High TEM7 expression was found in tumor samples 
of 29 women (41%) of whom 21 (72%) died of the disease. 
In the group of women with high TEM7 tumor expression 
a 5-year OS was 25% and it was not statistically different 
from the group of women with low TEM7 tumor expression 
in whom OS was 21% after 5 years. DSF rate in women with 
low TEM7 tumor expression was 8% and, although lower 
than in the high TEM7 expression group where DSF was 
20%, the differences between these two groups were not 
statistically significant (p = 0.74). No significant associations 
were found between TEM7 and nestin expression in tumor 
cells and between nestin-MVD and both OS and DFS. Figu-
res 5 and 6 present Kaplan-Meier curves for patients overall 
survival and DSF in groups with the high, medium and low 
nestin expression in tumor cells.
DISCUSSION
Malignant tumor aggressiveness can be determined 
with the use of various molecular markers. In particular, new 
angiogenesis markers are of great academic and clinical 
relevance because a marker-based approach can provide 
more precise categorization of various cancers. Moreover, 
new markers themselves can be used as specific targets 
for developing novel and more effective tumor-targeted 
therapies. One of the emerging possibilities is a specific 
blocking of tumor induced microvasculature. Since the role 
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of the above mentioned tumors angiogenic markers has not 
been precisely established to date, we have investigated the 
expression of TEM7, nestin and nestin-related microvessel 
density (MVD) in high-grade serous ovarian cancer sam-
ples. We have also studied their potential correlations with 
overall survival and disease-free survival of affected women. 
The main finding of our study is that nestin expression, but 
not TEM7 or nestin-MVD angiogenic activity measurements 
may assist in the prediction of OS and DFS in women with 
high grade serous ovarian cancer.
In our recent study we have demonstrated that nes-
tin-positive MVD could be used to identify malignant ovar-
ian  masses with high angiogenic activity, where tumor 
vasculature was formed [12]. Qin et al. [20] studied the 
expression profile of nestin in serous ovarian cancers and 
found its expression in 32.5% of cases. The overexpression of 
nestin was associated with the resistance to cisplatin-based 
chemotherapy and these women had shorter overall surviv-
al suggesting that nestin may be a novel and independent 
prognostic factor. Moreover, when nestin was found in tumor 
tissue its presence was positively correlated with increased 
expression of angiogenic markers such as EGFR (Epithelial 
Growth Factor Receptor), VEGF (Vascular Endothelial Growth 
Factor) and higher MVD in tumors [20]. He et al. [9] have 
studied nestin expression evaluated with the use of immu-
nohistochemistry (IHC) in 315 cases of various clinical and 
histological stages of epithelial ovarian neoplasms as well 
as in 52 control cases of normal ovarian epithelia. Sal et al. 
[21] have found increased concentrations of soluble nestin 
in the serum of ovarian cancer patients. Immunohistochemi-
cal results of their study revealed nestin expression was not 
present in benign masses and gradually increased from early 
Table 2. Nestin expression in tumor cells, MVD-nestin and TEM7 expression correlation with disease free survival (DSF) with overall survival (OS) 
rates in the studied group of women with HGSOC
 N (no. of patients)
OS
3-year
OS
5-year p
DSF
3-year
DSF
5-year p
Nestin expression in tumor cells
Low 33 42% 25%
p = 0.02
23% 23%
p = 0.01Medium 23 45% 24% 16% 10%
High 14 14% 0% 9% 0%
TEM-7 expression in tumor cell
Low 15 28% 21%
p = 0.44
8% 8%
p = 0.74Medium 26 48% 19% 21% 16%
High 29 32% 25% 20% 20%
Nestin-MVD SD = 17.3/HPF (min–max 7–30); MD = 16/HPF (range 12–23)
Low 0–15/HPF 26 44% 23%
p = 0.96
17% 13%
p = 0.39Medium (16–23/HPF) 27 32% 28% 21% 21%
High (24–30/HPF) 17 33% 11% 11% 11%
Figure 5. Kaplan-Meier curves for patients overall survival (OS) in the 
high, medium and low nestin expression groups
Figure 6. Kaplan-Meier curves for disease free survival (DSF) of 
women with the high, medium and low nestin expression groups
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borderline to advanced malignant ovarian tumors. These 
authors have concluded that nestin overexpression was as-
sociated with more advanced stage and higher histological 
grade of serous adenocarcinoma cases [21]. Zhang et al. [22] 
have suggested that nestin may be significantly associated 
with the resistance to chemotherapy as in their study the ex-
pression of nestin in chemoresistant cells was much higher 
when compared to parental hepatocellular cancer cells. The 
origin of nestin-positive vascular endothelial cells in tumor 
tissue is still controversial. Elevation of nestin expression 
likely corresponds to reorganization of intermediate fila-
ment network in the cytoskeleton of endothelial cells in 
the course of their maturation or adaptation to changes in 
growing tissues. The recent study performed by Osmann 
et al. [10] revealed expression of nestin in almost 50% of all 
EOC (Epithelial Ovarian Cancer) cases and it was found most 
often (60%) in serous type of tumors. Taken together these 
data suggested that nestin could be considered as a pro-
spective therapeutic target for ovarian cancer treatment. 
Wang et al. [23] have found that among all the cell sur-
face markers examined in their study only TEM7 expression 
was up-regulated upon endothelial cells capillary morpho-
genesis. In addition, inhibition of capillary morphogenesis 
by serum stimulation completely blocked TEM7 expression. 
In contrast, stimulation of endothelial cell capillary morpho-
genesis with PMA enhanced TEM7 expression. Furthermore, 
incubation of endothelial cells with a recombinant extra-
cellular domain of TEM7 blocked capillary morphogenesis 
in three-dimensional cultures. These results suggest that 
TEM7 is a novel protein whose cell surface expression is 
essential during endothelial cell capillary morphogenesis.
Bagley et al. [14] have investigated TEM7 as a possible 
target for therapeutic antiangiogenic intervention in can-
cer. TEM7 expression was assessed by in situ hybridization 
or by immunohistochemistry (IHC) in 130 formalin-fixed 
paraffin-embedded (FFPE) and 410 frozen human clinical 
specimens of cancer and in 301 normal tissue samples. In 
frozen tumor tissues, TEM7 mRNA and protein was detected 
in all but one of the cancer types tested and this mRNA was 
only rarely expressed in the control normal frozen tissues. In 
FFPE tumor tissues, TEM7 protein was detected by IHC in 
colon, breast, lung, bladder, ovarian and endometrial cancers 
and in sarcomas. In contrast, TEM7 protein was not detected 
in head and neck, prostate or liver cancers. Mehran et al. [24] 
hypothesized that TEMs may be detectable on circulating en-
dothelial cells (CECs) and that these circulating TEM(+) endo-
thelial cells (CTECs) may be a more specific marker for cancer 
and tumor response than standard CECs. Following treatment 
with various vascular-targeting agents, these authors have 
observed a decrease in CTEC that correlated with the reduc-
tions in tumor growth. Novel cancer-associated markers could 
potentially be used as a blood-based surrogates for assessing 
the presence of tumor vasculature and antiangiogenic drug 
activity. Taken together these data indicate that molecular 
factors that control malignant tumors angiogenesis formation 
could have a significant implication in future management of 
patients with advanced clinical stages of HGSOC.
CONCLUSIONS
Nestin as a marker of cancer stem cells may assist in the 
prediction of OS and DFS in women with high grade serous 
ovarian cancer. Nestin may also be considered a novel the-
rapeutic target for antiangiogenic agents.
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